30 Sept 2026, 09:27
Company Update—
OSLONCOSIL MEDICAL LTD
Announcement history available from 1 August 2025
Fromto
28 Sept 2026, 13:26
Meetings & Governance—
15 Sept 2026, 09:04
Securities Administration—
14 Sept 2026, 16:52
Substantial Holders—
14 Sept 2026, 08:39
Substantial Holders—
10 Sept 2026, 11:21
Securities Administration—
10 Sept 2026, 11:20
Securities Administration—
10 Sept 2026, 11:16
Securities Administration—
9 Sept 2026, 08:43
Company UpdateMS
8 Sept 2026, 09:40
Company Update—
7 Sept 2026, 17:12
Securities Administration—
7 Sept 2026, 17:11
Capital RaisingMS
2 Sept 2026, 11:33
Company Update—
2 Sept 2026, 10:27
Company Update—
28 Aug 2026, 16:03
Company Administration—
28 Aug 2026, 15:58
Financial ResultsMS
21 Aug 2026, 16:52
Substantial Holders—
20 Aug 2026, 09:22
Substantial Holders—
17 Aug 2026, 16:46
Securities Administration—
17 Aug 2026, 15:09
Presentations—
17 Aug 2026, 08:35
Company UpdateMS
30 July 2026, 08:42
Quarterly ReportsMS
24 July 2026, 08:40
Company Update—
23 July 2026, 15:25
Securities Administration—
20 July 2026, 08:31
Company Update—
17 July 2026, 15:31
Securities Administration—
15 July 2026, 08:57
Presentations—
14 July 2026, 08:54
Company Update—
13 July 2026, 08:39
Company UpdateMS
6 July 2026, 08:49
Company Update—
3 July 2026, 08:27
Company UpdateMS
2 July 2026, 08:46
Company UpdateMS
30 June 2026, 08:47
Company Administration—
29 June 2026, 15:54
Securities Administration—
12 June 2026, 09:04
Company Update—
12 June 2026, 08:30
Presentations—
11 June 2026, 10:12
Substantial Holders—
10 June 2026, 09:04
Company Update—
9 June 2026, 09:48
Presentations—
9 June 2026, 09:48
Company UpdateMS
9 June 2026, 09:47
Company UpdateMS
4 June 2026, 09:09
Trading Halt / SuspensionMS
1 June 2026, 08:59
Company Update—
28 May 2026, 09:05
Company Update—
27 May 2026, 15:22
Securities Administration—
27 May 2026, 15:20
Securities Administration—
25 May 2026, 15:49
Company Administration—
22 May 2026, 09:14
Company Update—
20 May 2026, 09:17
Company UpdateMS
15 May 2026, 08:31
Company Update—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 30 Sept 2026, 09:27 | OncoSil Clinical Data to be Presented at EANM 2026 | Company Update | — | 11001 | |
| 28 Sept 2026, 13:26 | Notice of AGM date | Meetings & Governance | — | 08006 | |
| 15 Sept 2026, 09:04 | Notice under ASX Listing Rule 3.10A | Securities Administration | — | 06009 | |
| 14 Sept 2026, 16:52 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 14 Sept 2026, 08:39 | Change in substantial shareholding from AEF | Substantial Holders | — | 02002 | |
| 10 Sept 2026, 11:21 | Notice Under Section 708A | Securities Administration | — | 06018 | |
| 10 Sept 2026, 11:20 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 10 Sept 2026, 11:16 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 9 Sept 2026, 08:43 | Australian Manufacturing Facility Achieves ISO 13485 | Company Update | MS | 11001 | |
| 8 Sept 2026, 09:40 | 100th Patient Treated with OncoSil device in Spain | Company Update | — | 11001 | |
| 7 Sept 2026, 17:12 | Proposed issue of securities - OSL | Securities Administration | — | 06013 | |
| 7 Sept 2026, 17:11 | OSL Secures $5.6 million from Major Institutional Investors | Capital Raising | MS | 06003 | |
| 2 Sept 2026, 11:33 | OncoSil submits US Reimbursement Application (Updated) | Company Update | — | 11001 | |
| 2 Sept 2026, 10:27 | OncoSil submits US Reimbursement Application | Company Update | — | 11001 | |
| 28 Aug 2026, 16:03 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 28 Aug 2026, 15:58 | Appendix 4E and Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 21 Aug 2026, 16:52 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 20 Aug 2026, 09:22 | Change in substantial shareholding from AEF | Substantial Holders | — | 02002 | |
| 17 Aug 2026, 16:46 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 17 Aug 2026, 15:09 | Investor Webinar Presentation | Presentations | — | 03026 | |
| 17 Aug 2026, 08:35 | OncoSil Receives FDA Approval for Distal Cholangiocarcinoma | Company Update | MS | 11001, 14014 | |
| 30 July 2026, 08:42 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 24 July 2026, 08:40 | New Independent Study Confirms OncoSil Dose Flexibility | Company Update | — | 11001 | |
| 23 July 2026, 15:25 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 20 July 2026, 08:31 | OncoSil Medical Receives Saudi Arabia FDA Approval | Company Update | — | 11001 | |
| 17 July 2026, 15:31 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 15 July 2026, 08:57 | Investor Presentation | Presentations | — | 03026 | |
| 14 July 2026, 08:54 | OSPREY Registry Abstract Accepted for EANM 2026 Congress | Company Update | — | 11001 | |
| 13 July 2026, 08:39 | OncoSil Medical Completes Manufacturing Validation | Company Update | MS | 11001 | |
| 6 July 2026, 08:49 | TRIPP-FFX Results Presented at ESMO GI 2026 | Company Update | — | 11001 | |
| 3 July 2026, 08:27 | OncoSil Medical Files for FDA Approval | Company Update | MS | 11001 | |
| 2 July 2026, 08:46 | OncoSil Selected for Major European Pancreatic Cancer Study | Company Update | MS | 11001 | |
| 30 June 2026, 08:47 | TRIPP-FFX Abstract Published on ESMO GI 2026 Website | Company Administration | — | 12008 | |
| 29 June 2026, 15:54 | Notice under ASX Listing Rule 3.10A | Securities Administration | — | 06009 | |
| 12 June 2026, 09:04 | Publication verifies OncoSil strong localisation in pancreas | Company Update | — | 11001 | |
| 12 June 2026, 08:30 | OncoSil Medical Launches Investor Hub | Presentations | — | 14014 | |
| 11 June 2026, 10:12 | Change in substantial shareholding from AEF | Substantial Holders | — | 02002 | |
| 10 June 2026, 09:04 | TRIPP FFX accepted for oral presentation at ESMO GI 2026 | Company Update | — | 11001 | |
| 9 June 2026, 09:48 | US FDA HDE and TRIPP-FFX Study Presentation | Presentations | — | 03026 | |
| 9 June 2026, 09:48 | OncoSil progresses HDE with US FDA | Company Update | MS | 11001, 14014 | |
| 9 June 2026, 09:47 | TRIPP-FFX Clinical Trial Meets Co-Primary Endpoints | Company Update | MS | 09014, 11001, 14014 | |
| 4 June 2026, 09:09 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 1 June 2026, 08:59 | TRIPP FFX Clinical Trial to Report Results in June | Company Update | — | 11001 | |
| 28 May 2026, 09:05 | Key New Ethics Approval for Italian Patient Registry | Company Update | — | 11001 | |
| 27 May 2026, 15:22 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 27 May 2026, 15:20 | Notification regarding unquoted securities - OSL | Securities Administration | — | 06021 | |
| 25 May 2026, 15:49 | Appointment of Company Secretary | Company Administration | — | 12007 | |
| 22 May 2026, 09:14 | New Clinical Evidence for OncoSil Device Presented at ASCO | Company Update | — | 11001, 12008 | |
| 20 May 2026, 09:17 | OncoSil Medical Receives TGA Approval in Australia | Company Update | MS | 11001 | |
| 15 May 2026, 08:31 | OSPREY Interim Results Presented at ESGE Days 2026 | Company Update | — | 11001 |
1–50 of 133
1 / 3